Phase 3 Crohn's Disease and Colitis Trial, Recruiting NCT03804931 Sponsor: Guangzhou First People's Hospital Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 3 Crohn's Disease and Colitis Trial, Recruiting

NCT03804931
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have active ulcerative colitis that is considered moderate to severe (based on a scoring system called the Mayo score, with a result above 6)
  • You have previously used or are currently using a medication called 5-ASA (a common treatment for bowel inflammation) safely
  • You are able to have an endoscopy (a camera examination of the inside of your bowel)

Who may not be able to join:

  • You have taken antibiotics in the last 7 days
  • You are considered at high risk of a serious bowel complication called toxic megacolon (a dangerous swelling of the large intestine — confirm with trial site)
  • You have been found to have colon cancer or abnormal growths in your bowel
  • You have another serious illness affecting your heart, lungs, digestive system, or kidneys

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yuqiang Nie, MD, Guangzhou First People's Hospital

Phone: 86-13631316718

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Guangzhou First People's Hospital
Registry
ClinicalTrials.gov
Start date
20 January 2019
Est. completion
31 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Clinical remission in patient as assessed using Mayo score; Clinical improvement in patient as assessed using Mayo score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov